FindTrial
Sign In

Atezolizumab Placebo

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Fallopian Tube CancerMelanomaOvarian CancerPeritoneal NeoplasmsTriple-Negative Breast Cancer

Phase 3

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
CompletedNCT02908672
Hoffmann-La RocheMelanoma
Start: 2017-01-13End: 2024-07-01Updated: 2025-07-20
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
CompletedNCT03038100
Hoffmann-La RocheFallopian Tube Cancer, Ovarian Cancer, Peritoneal Neoplasms
Start: 2017-03-08End: 2022-08-12Updated: 2023-02-17
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
CompletedNCT03125902
Hoffmann-La RocheTriple-Negative Breast Cancer
Start: 2017-08-25End: 2023-01-17Updated: 2024-03-26

Related Papers

Impact of proton pump inhibitor (PPI) pharmacogenomics (PGx) on toxicities associated with immune checkpoint inhibitor (ICI) therapy.
Journal of Clinical Oncology2025-05-28
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Clinical Cancer Research2023-12-0745 citations
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
2023-08-2318 citations
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
Cancer Immunology Immunotherapy2023-06-0918 citations
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
2023-05-0135 citations
Abstract 5702: Ovarian cancer tumor microenvironment and atezolizumab (atezo) clinical activity: IMagyn050 sub-study
Cancer Research2023-04-042 citations
Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma
BMC Health Services Research2023-01-186 citations
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
2022-11-2965 citations
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Journal for ImmunoTherapy of Cancer2022-06-0122 citations
Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in <i>BRAF</i><sup>V600</sup> mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.
Journal of Clinical Oncology2022-06-015 citations
Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs).
Journal of Clinical Oncology2022-06-014 citations
Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial
Cancer Research2022-02-159 citations
Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF<sup>V600</sup> mutation-positive melanoma.
2022-02-0422 citations
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for<i>BRAF</i>V600–Mutant Unresectable or Metastatic Melanoma
Journal of Clinical Oncology2022-01-14151 citations
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
ESMO Open2021-11-1910 citations
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
2021-07-01536 citations
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Journal of Clinical Oncology2021-04-23372 citations
Bevacizumab + Atezolizumab for Newly Diagnosed Stage III/IV Ovarian Cancer
Oncology Times2020-11-11
307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study
Regular and Young Investigator Award Abstracts2020-11-013 citations
301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
Regular and Young Investigator Award Abstracts2020-11-01

9 more papers not shown